Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Ravin Ratan, MD, MEd

Advertisement

Articles by Ravin Ratan, MD, MEd

Ravin Ratan, MD, MEd

Dr. Ratan on the Steps of Diagnosing Desmoid Tumors

ByRavin Ratan, MD, MEd
January 3rd 2022

Ravin Ratan, MD, MEd, discusses the steps that should be taken to diagnose desmoid tumors.

Advertisement

Latest Updated Articles

  • Ravin Ratan, MD, MEd
    Dr. Ratan on the Steps of Diagnosing Desmoid Tumors

    January 3rd 2022



Advertisement
Advertisement

Trending on OncLive

1

Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management

2

Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL

3

CHMP Recommends Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ Metastatic TNBC

4

CHMP Recommends T-DXd Plus Pertuzumab for First-Line HER2-Positive Metastatic Breast Cancer

5

Breast Cancer Buzz at ASCO 2026: De-Escalation Strategies, Targeted Therapies, and More

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us